Nocion
is a Massachusetts-based biopharmaceutical company that researches and develops small-molecule therapies for the treatment of serious conditions including cough and itch... Read moreNocion
is a Massachusetts-based biopharmaceutical company that researches and develops small-molecule therapies for the treatment of serious conditions including cough and itch... Read more
News
Nov 19, 2024
OINDPnews
Nocion: Nocion initiates Phase 2b trial of NOC-110 taplucainium DPI for the treatment of chronic cough
Nov 18, 2024
Business Wire
Press Release: Nocion : Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study
Apr 02, 2024
FinanzNachrichten
Nocion: Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment
Mar 06, 2024
FinSMEs
Nocion: Nocion Therapeutics Raises $62M in Series B Financing
Mar 05, 2024
OINDPnews
Nocion: Nocion raises $62 million for Phase 2b study of taplucanium DPI for the treatment of chronic cough
Mar 04, 2024
Endpoints News
Nocion: Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSK
Sep 01, 2021
OINDPnews
Nocion: Nocion Therapeutics announces Phase 2a trial of inhaled NTX-1175 charged sodium channel blocker for chronic cough
Sep 29, 2020
Contract Pharma
Nocion: Catalent Provides Mfg. Support for Nocion Program
Sep 01, 2020
PR Newswire
Press Release: Nocion : Nocion Therapeutics Advances to Clinical Stage and Expands Leadership
Jan 06, 2020
OINDPnews
Nocion: Pulmatrix announces collaboration with Nocion Therapeutics
Nocion Competitors
1
2
3
4
5
6
7
8
9
10